A total of 23 providers completed the survey  Age: 56±10 years, female: 48%; Titles:
• Physicians: 52% (N=12)
• Nurses or nurse practitioners: 43% (N=11) Most worked at academic hospitals: 78%  61% had more than 10 years of experience (range: 5-40 years) (Figure 2 )  Encountered patients with worse symptoms toward the end of an injection cycle: 70% (5 MDs and 11 nurses)  Top three concerns about barriers to disease management among MD doctors ( Figure  3 ): Side effects (100%), financial issues (89%), and therapy being too complicated or inconvenient to patients (56%)
RESULTS
Leading barriers to treatment adherence from the healthcare provider perspective  Treatment side effects  Financial issues  Inconvenience
CONCLUSIONS
 A web-based cross-sectional survey was conducted from August -October, 2014  Healthcare providers who had experience in treating acromegaly patients were surveyed. The sampling frame showed as flowchart.  Information collected:
• Barriers to treatment adherence • Influence on the treatment algorithm based on their experiences and perspectives.
METHODS
To assess the barriers to treatment adherence on disease management of acromegaly from the provider prospective
OBJECTIVES
 Acromegaly is a chronic disorder characterized by autonomous overproduction of growth hormone (GH) predominantly due to a benign pituitary adenoma  The excess GH results in increased secretion of insulin-like growth factor 1 (IGF-1), both of which are responsible for multiple significant comorbidities 1  Acromegaly is a rare disorder 1,2 :
• Prevalence: 58-130 cases per million adults • Incidence of 3.3 cases per million per year  Delayed diagnosis 1-3 :
• The course of the disease is insidious and slowly progressive • A delay of 7-10 years in diagnosis from the presentation of symptoms is often seen  Optimal disease management of acromegaly requires a highly coordinated approach involving numerous specialties and lifetime monitoring  Current disease control is suboptimal:
• While successful disease control has been shown to potentially normalize mortality in the acromegaly patient, disease control is quite elusive as over 50% of patients with acromegaly are not effectively treated 2,3 
Figure 3 CONCERNS ABOUT BARRIERS TO DISEASE MANAGEMENT (n=12)
 Nurses with experiences of somatostatin analog (SSA) injections: 82%  Concerns of SSA injection among nurses: 55% The most common concerns:
• Side effects (e.g., pain, erythema, hematoma)
• Preparation time for injection too long  Consideration of new oral alternative:
All physicians and nurses with SSA injection experience (n=21) would consider offering an oral therapy to patients if it has comparable efficacy and safety to the current long acting SSA treatments
RESULTS

50%
41.67% 
DISCUSSION
 Significance: Understanding current situation of acromegaly management in order to • Recognize current barriers to treatment • Examine physicians' perceptions • Access providers' preference to make better decision on treatment for acromegaly • Make prompt efforts to improve the health care experience  Barriers to treatment adherence 4 • Patients' perception affect their compliance since the treatment of acromegaly involves different modalities that are long-term and/or have long-lasting consequences; and • Having to get injections periodically over a life-time and being exposed to certain side-effects may alter patients' perception of their disease and medications: 100% concern about side effect.
• Less convenient treatments: 56% concern of inconvenient or therapy too complicated • Less effective treatments: 55% nurse concern about Preparation time for injection  Limitation:
Sample size is small, which reduces the strength of the statistical results.
